Trulieve Cannabis (TCNNF) Cash from Financing Activities (2020 - 2026)
Trulieve Cannabis (TCNNF) recorded quarterly Cash from Financing Activities of $54.8 million in Q1 2026, up 121.47% quarter-over-quarter from -$255.4 million in Q4 2025, and up 1318.92% on a YoY basis from $3.9 million in Q1 2025.
Trulieve Cannabis (TCNNF) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Trulieve Cannabis' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $54.8 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 1318.92% year-over-year to $54.8 million; the TTM figure through Mar 2026 stood at -$211.2 million (down 480.4% YoY), while the FY2025 annual figure was -$270.5 million, down 708.93% from the prior year.
- Cash from Financing Activities was $54.8 million for Q1 2026 at Trulieve Cannabis, up from -$255.4 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $85.9 million in Q4 2022 to a low of -$255.4 million in Q4 2025.
- Historically, Cash from Financing Activities has averaged -$14.5 million across 5 years, with a median of -$4.8 million in 2025.
- The sharpest annual moves came in 2025 and 2026: Cash from Financing Activities sank 3917.49% in 2025, then soared 1318.92% in 2026.
- A 5-year view of Cash from Financing Activities shows it stood at $85.9 million in 2022, then slumped by 233.94% to -$115.0 million in 2023, then jumped by 94.47% to -$6.4 million in 2024, then tumbled by 3917.49% to -$255.4 million in 2025, then soared by 121.47% to $54.8 million in 2026.
- The last three Cash from Financing Activities figures came in at $54.8 million (Q1 2026), -$255.4 million (Q4 2025), and -$4.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.97 Bn | 36.23 Bn | 1.97 Bn | 13.00 Mn |
| 2 | Zoetis | 33.59 Bn | 31.65 Bn | 1.62 Bn | -840.00 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | -1.48 Bn |
| 4 | Neurocrine Biosciences | 16.10 Bn | 14.78 Bn | 800.70 Mn | -86.10 Mn |
| 5 | Aurora Cannabis | 15.56 Bn | 15.47 Bn | 21.72 Mn | - |
| 6 | Elanco Animal Health | 12.04 Bn | 11.61 Bn | 785.00 Mn | -65.00 Mn |
| 7 | Alkermes | 7.36 Bn | 6.84 Bn | -116.06 Mn | 1.47 Bn |
| 8 | Lantheus Holdings | 6.74 Bn | 6.24 Bn | 230.92 Mn | -11.62 Mn |
| 9 | Liquidia | 6.27 Bn | 6.04 Bn | 121.79 Mn | -18.05 Mn |
| 10 | Trulieve Cannabis | - | - | 170.08 Mn | 54.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 54.83 Mn |
| Mar 31, 2026 | 54.83 Mn |
| Dec 31, 2025 | -255.39 Mn |
| Dec 31, 2025 | -255.39 Mn |
| Sep 30, 2025 | -4.77 Mn |
| Sep 30, 2025 | -4.77 Mn |
| Jun 30, 2025 | -5.84 Mn |
| Jun 30, 2025 | -5.84 Mn |
| Mar 31, 2025 | -4.50 Mn |
| Mar 31, 2025 | -4.50 Mn |
| Dec 31, 2024 | -6.36 Mn |
| Dec 31, 2024 | -6.36 Mn |
| Sep 30, 2024 | -16.36 Mn |
| Sep 30, 2024 | -16.36 Mn |
| Jun 30, 2024 | -9.17 Mn |
| Jun 30, 2024 | -9.17 Mn |
| Mar 31, 2024 | -1.55 Mn |
| Mar 31, 2024 | -1.55 Mn |
| Dec 31, 2023 | -114.99 Mn |
| Dec 31, 2023 | -114.99 Mn |